These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 28031564)

  • 1. R&D returns continue to fall.
    Mullard A
    Nat Rev Drug Discov; 2016 Dec; 16(1):9. PubMed ID: 28031564
    [No Abstract]   [Full Text] [Related]  

  • 2. Crowdsourcing in pharmaceutical R&D: a revolutionary concept or nothing new?
    Song CH
    Pharm Pat Anal; 2016 Sep; 5(6):355-360. PubMed ID: 27804785
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: The Innovative Medicines Initiative--collaborations are key to innovating R&D processes.
    Laverty H; Goldman M
    Biotechnol J; 2014 Sep; 9(9):1095-6. PubMed ID: 25174501
    [No Abstract]   [Full Text] [Related]  

  • 4. Organizing for innovation: towards successful translational research.
    West W; Nightingale P
    Trends Biotechnol; 2009 Oct; 27(10):558-61. PubMed ID: 19683820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Portfolio management in early stage drug discovery - a traveler's guide through uncharted territory.
    Betz UA
    Drug Discov Today; 2011 Jul; 16(13-14):609-18. PubMed ID: 21600301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The seven types of drug discovery waste: toward a new lean for the drug industry.
    Uitdehaag JC
    Drug Discov Today; 2011 May; 16(9-10):369-71. PubMed ID: 21354473
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk mitigation in academic drug discovery.
    Ellinger B; Gribbon P
    Expert Opin Drug Discov; 2016; 11(4):333-6. PubMed ID: 26894865
    [No Abstract]   [Full Text] [Related]  

  • 8. Developing pharmacogenetic evidence throughout clinical development.
    Burns DK
    Clin Pharmacol Ther; 2010 Dec; 88(6):867-70. PubMed ID: 20981004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fragment-based lead discovery grows up.
    Baker M
    Nat Rev Drug Discov; 2013 Jan; 12(1):5-7. PubMed ID: 23274457
    [No Abstract]   [Full Text] [Related]  

  • 10. Trial watch: Clinical trial cycle times continue to increase despite industry efforts.
    Martin L; Hutchens M; Hawkins C
    Nat Rev Drug Discov; 2017 Mar; 16(3):157. PubMed ID: 28184041
    [No Abstract]   [Full Text] [Related]  

  • 11. An audience with Patrick Vallance.
    Vallance P
    Nat Rev Drug Discov; 2010 Nov; 9(11):834. PubMed ID: 21030993
    [No Abstract]   [Full Text] [Related]  

  • 12. An audience with...Luca Santarelli. Interview by Alexandra Flemming.
    Santarelli L
    Nat Rev Drug Discov; 2013 Jan; 12(1):14-5. PubMed ID: 23274461
    [No Abstract]   [Full Text] [Related]  

  • 13. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.
    Jones HM; Chen Y; Gibson C; Heimbach T; Parrott N; Peters SA; Snoeys J; Upreti VV; Zheng M; Hall SD
    Clin Pharmacol Ther; 2015 Mar; 97(3):247-62. PubMed ID: 25670209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An industry perspective on drug target validation.
    Jones LH
    Expert Opin Drug Discov; 2016 Jul; 11(7):623-5. PubMed ID: 27111834
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacotherapy crisis in the spotlight--is open collaboration between academia and industry the answer?
    Kaski JC
    Cardiovasc Drugs Ther; 2011 Apr; 25(2):187-8. PubMed ID: 21503624
    [No Abstract]   [Full Text] [Related]  

  • 16. Continuous flow synthesis. A pharma perspective.
    Malet-Sanz L; Susanne F
    J Med Chem; 2012 May; 55(9):4062-98. PubMed ID: 22283413
    [No Abstract]   [Full Text] [Related]  

  • 17. Q&A: Bernard Munos.
    Bender E
    Nature; 2016 May; 533(7602):S59. PubMed ID: 27167392
    [No Abstract]   [Full Text] [Related]  

  • 18. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
    [No Abstract]   [Full Text] [Related]  

  • 19. What is the most important approach in current drug discovery: doing the right things or doing things right?
    Elebring T; Gill A; Plowright AT
    Drug Discov Today; 2012 Nov; 17(21-22):1166-9. PubMed ID: 22569181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Art of Virtualizing Pharma R&D.
    Schuhmacher A; Gassmann O; Kuss M; Hinder M
    Drug Discov Today; 2019 Nov; 24(11):2105-2107. PubMed ID: 31323393
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.